Pregnancy after pituitary surgery does not influence the recurrence of Cushing’s disease

Lia Mesquita Lousada1 · Mariuxi Jacqueline Borja Tapia1 · Valter Angelo Sperling Cescato2 · Gilberto Ochman da Silva2 · Nina Rosa Castro Musolino2 · Maria Candida Barisson Villares Fragoso3 · Marcello Delano Bronstein1,4 · Marcio Carlos Machado1,4,5

Received: 17 February 2022 / Accepted: 18 July 2022 / Published online: 5 August 2022
© The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022

Abstract
Purpose
Pregnancy is associated with the activation of the hypothalamus–pituitary–adrenal axis, which can cause a misdiagnosis of Cushing’s syndrome. The aim of this study is to evaluate the impact of pregnancy after pituitary surgery on the recurrence rate in Cushing’s disease (CD) patients.

Methods
This was a retrospective study in a tertiary center. Between 1990 and 2020, 355 CD patients underwent pituitary surgery. Of those, we included 113 female patients who were ≤ 45 years old (median age of 32 years, 14–45), PS remission, a follow-up of ≥6 months (median of 122 months, 6–402) and an available obstetric history. Recurrence was defined as the diagnosis of Cushing’s syndrome via at least two altered first-line methods. The patients were divided into two subgroups according to pregnancy: no pregnancy or pregnancy prior to CD diagnosis (NP/PP) and pregnancy after CD pituitary surgery (PA).

Results
Overall, recurrence occurred in 43 out of 113 patients (38%). A higher recurrence rate was seen in the PA subgroup (11/22, 50%), but there was no significant difference between the NP/PP subgroup (32/91, 35%). No difference in survival-free recurrence (SFR) was found between NP/PP and PA subgroups. The lower SFR was related to a higher PS plasma ACTH and normal pituitary at pathological analyses.

Conclusions
There was no difference in the recurrence rate in patients according to pregnancy history. Other studies with higher numbers of patients are needed to confirm these data.

Keywords
Cushing’s disease · Pituitary surgery · Pregnancy · Recurrence

Introduction
Transsphenoidal selective adenomectomy by an experienced pituitary surgeon is the optimal treatment option for Cushing’s disease (CD) in adult and pediatric patients [1]. Overall, the CD has a post-surgical (PS) remission rate of approximately 80%, including approximately 80–85% for microadenomas and a lower rate for macroadenomas (approximately 60%) [1–4].

However, long-lasting remissions decrease in the follow-up due to a significant recurrence rate. Therefore, the term “remission” is preferable to “cure” in PS CD patients.

The recurrence rate is approximately 15–25% within 5–10 years of an initially successful surgery [2, 3, 5].

Among unfavorable prognosis factors for recurrence are a PS serum cortisol (Fs) >2–5 µg/dL, a high PS ACTH, an early recovery of hypothalamus-pituitary-adrenal (HPA) axis function with a short period of need for
glucocorticoid replacement, an absence of a return of the circadian rhythm of cortisol secretion and positive responses of ACTH and/or serum cortisol to PS desmopressin/CRH stimulation [6, 7].

It had been previously demonstrated that pregnancy is associated with the following: activation of the HPA axis; serial increases in ACTH and cortisol as a result of CRH and ACTH placentation production; and maximal levels of cortisol during the third trimester [8–10]. Besides these factors, gestation constitutes a state of “hypercortisolism” and the diagnosis of true endogenous Cushing’s syndrome during pregnancy is a real challenge especially during the second and third trimesters.

Moreover, hormonal changes that occur during the pregnancy may stimulate putative tumor cell remnants. However no previous study evaluated mainly the influence of pregnancy on the recurrence rate in a group of reproductive-age female CD patients.

Therefore, since hyperstimulation of HPA axis during pregnancy and considering the clinical observation that several recurrent CD episodes occur after pregnancy, the aim of this study was to evaluate the impact of pregnancy history in recurrence rate in CD PS patients.

Material and methods

Patients

We performed a retrospective study in a tertiary hospital with 355 patients whose diagnosis confirmed CD and who were admitted between 1990 and 2020. All patients had transsphenoidal surgery, with a minimum follow-up of six months (median of 83 months, 6–415). Overall, the remission rate was 69.3% (246/355), and 76 patients (30.9%) presented with recurrence in the follow-up. A considerable part of this series (n = 317) was previously published in 2016, when the study focused on the differences between microadenomas [MIC] and macroadenomas [MAC] (n = 74) CD patients [4]. Therefore, this actual study can be considered a sub-study of original although it focuses on different aspects of the previous report. In the 2016 study, recurrence rate was 26.6%, MAC were 23%, tumor invasion at initial pituitary MRI was presented in 5.7% in entire cohort (23% of MAC cases) and normal pituitary at post-surgical analyses was presented in 17% of cases (25% of MIC cases).

For this study, inclusion criteria were women ≤45 years old with postoperative remission and obstetric history available. The Ethical and Research Committees of our institution approved the study.

All the patients were seen by two of the authors at least at the diagnosis, before surgery and over the study.

The diagnosis of ACTH-dependent CS was based on typical clinical features and standard hormonal criteria. Additionally, desmopressin had been used in cases of doubtful or discordant methods for CS diagnosis [11].

Differential diagnosis of ACTH-dependent CS was achieved by pituitary MRI, the response to human or ovine CRH, a high-dose dexamethasone suppression test (HDDST) and a bilateral inferior petrosal sinus sampling (BIPSS) in cases of equivocal or negative MRI for a pituitary lesion suggestive of adenoma [12].

The diagnosis of CD was confirmed by histological features which were identified as pituitary adenoma with ACTH immunostaining in the majority of cases. In the remaining patients without ACTH immunostaining, the diagnosis of CD was established by post surgical remission and/or by a central to peripheral ACTH gradient in the BIPSS. Only two pathologists performed all pathological analyses during the study period.

Post-surgical remission was defined as a low (<5 µg/dL) or undetectable Fs levels 18–24 h after the last dose of oral cortisone acetate or hydrocortisone, which were collected in the fifth postoperative day (mean), clinical for adrenal insufficiency, need for glucocorticoid replacement, disappearance of clinical of hypercortisolism and normal urinary cortisol - 24 h (UC) levels (after glucocorticoid withdraw) for a minimum of six months of pituitary surgery. A post-surgical desmopressin test was used to predict recurrence risk [6].

Recurrence was defined as the reappearance of clinical symptoms and signs of hypercortisolism and at least two first-line methods pointing to the activity of CD after more than six months post-surgery.

Pituitary surgery was done by one neurosurgeon from 1982–1999 and by another two neurosurgeons after 2000 (VASC and GOS). The mean follow-up of patients was 122 months (range 6–402).

The obstetric history was collected personally during outpatient visits (MCM) or through telephone or email contacts (LML, MJBT and MCM), emphasizing the number and timing of pregnancies in relation to CD diagnosis, history of maternal and fetal complications and newborn data (size and weight).

Hormone assays

Serum cortisol was measured by fluoroimmunoassay in an AutoDelfia System (Wallac, Perkin Elmer, Turku, Finland) with an intra-assay (IA) variation coefficient (VC) of 8.2% and an inter-assay (IE) VC of 7.5%, and a sensitivity of 1 µg/dL until February 2009. From this date on, Fs was measured by a chemiluminescence assay (CLA) (DPC, Siemens, Los Angeles, CA, USA) with an IA-VC of 7.4% and an IE-VC of 8.6% with the same sensitivity of 1 µg/dL.
For the measurement of UC without extraction, we used the same assays for Fs. Until June 2010, nocturnal salivary cortisol (NSC) was measured by radioimmunoassay (DPC, Siemens, Los Angeles, CA, USA) with an IA- and IE-VC of <20% with the sensitivity of 0.1 µg/dL. From this date on, an ELISA (Salimetrics®, LLC, State College, PA, USA) was used with an IA- and IE-VC < 6.3% with the sensitivity of 0.016 µg/dL. From 1992–2002 and from 2003–2007, ACTH was measured by an immunoradiometric method (CIS bio International, Gif/Yvette, France) with an IE-VC < 14% and a sensitivity of 16 pg/mL. From 2002 to 2003, ACTH was measured by a CLA (Nichols Advantage, CA, USA) with an IE-VC < 12.6% and a sensitivity of 10 pg/mL. After 2007, another CLA (DPC, Siemens, Los Angeles, CA, USA) was used with an IA-VC of 4.9% and an IE-VC of 6.1% with a sensitivity of 5 pg/mL.

### Statistical analysis

The chi-square test was conducted to verify the association between categorical variables in contingency tables, and Fisher’s exact test was adopted in 2 × 2 tables whenever at least one expected frequency was less than 5.

For normally distributed variables, the analysis of variance was used to verify association between continuous data and categorical variables with three categories, and the Student t-test was used for variables with two categories. For non-normally distributed variables, the Mann–Whitney U test was used to verify associations between continuous data, and the Kruskal–Wallis test was used for categorical variables with two categories. The Shapiro–Wilk test was conducted to verify non-normal distributions for continuous variables.

The follow-up time was considered as the period of months between the date of pituitary surgery or until the date of death or the last date with information for censored cases (alive patients or lost for the follow-up).

The Kaplan–Meier method was used to estimate the overall survival probability and the log-rank test to compare survival curves.

The level of significance of 5% was considered for all statistical tests. Statistical computer software STATA® 10.0 (StataCorp LLC, College Station, Texas, USA) was used to conduct all statistical analysis.

### Results

#### Patient subgroups according to pregnancy history

There was included 113 female patients with a median age of 32 years (14–45). These selected patients were divided into two subgroups according to their obstetric history: no-pregnancy or pregnancy prior to CD diagnosis (NP/PP) and pregnancy after CD surgery (PA) (Table 1).

The majority of laboratory and imaging data at diagnosis and the in post-surgical time were similar between two subgroups, except by a lower age at diagnosis and a higher follow-up in the PA subgroup.

### Post-surgical and long-term outcome

Of the 113 patients included in this study, 43 patients (38%) had a recurrence, with a median of 48 months (8–240) after pituitary surgery. Some risk factors were presented in these 113 patients: 30% of MAC, normal pituitary at post-surgical analyses was presented in 12.4% of cases, relative small period (<12 months) of post-surgical glucocorticoid replacement in the PA subgroup and four cases with sinus cavernous invasion at initial pituitary MRI (Tables 1 and 2).

The patients who recurred were slighted younger at Cushing’s diagnosis (29.0 ± 7.0 vs. 31.9 ± 7.7 years-old, p = 0.047), presented a larger follow-up PS time (173.9 ± 92.2 vs. 113.7 ± 86.3 months, p = 0.001) and a higher number of sinus cavernous invasion (Table 2). Although the higher percentage of pregnancies after surgery in recurrence patients, the survival-free recurrence curve was not different between two subgroups according to pregnancy history (p = 0.531) (Fig. 1). A lower survival-free recurrence was related to higher PS plasma ACTH more than 68.2 pg/mL at 5th PS Day and normal pituitary at pathological analyses (data not shown).

### Obstetric and delivery history

Of 113 patients of this study, 67 patients (59.3%) have a positive history of pregnancy, and most of them were pregnant prior to CD diagnosis (67.2%).

Overall, there were 135 pregnancies in 67 patients, 2.0 per patient. There is no difference in a number of pregnancies per patient, maternal weight gain, type of delivery (normal or cesarean), delivery time (term or premature), newborn weight and newborn size, between remission and recurrence patients (Table 3).

Considering data from pregnancy/newborn closer to CD diagnosis or recurrence, the maternal complications occurred in 13 patients: eight in remission and five in recurrence cases; complications included arterial hypertension of pregnancy, preeclampsia, gestational diabetes mellitus, fetal macrosomia and panic syndrome.

Fetal complications occurred in 11 cases, four in remission and seven in recurrence cases; complications included neonatal jaundice, prematurity, neonatal hypoxia, oligodramnious and small-for-gestational-age fetus.
Table 1  Patient subgroups according to pregnancy history

| Parameter                                      | NP/PP       | PA          | p        |
|-----------------------------------------------|-------------|-------------|----------|
| Number (%)                                    | 91 (80.5)   | 22 (19.5)   | NA       |
| Age: years (mean ± SD)º                       | 31.7 ± 7.6  | 27.2 ± 6.5  | 0.011*   |
| Fs 800 h: µg/dL (mean ± SD)º                  | 23.2 ± 8.0  | 32.3 ± 40.0 | 0.843    |
| NSC: ng/dL (mean ± SD)º                       | 617.4 ± 574.8 | 2695.6 ± 5973.8 | 0.393  |
| UC: µg/24 h (mean ± SD)º                      | 694.4 ± 472.8 | 2276.5 ± 7236.2 | 0.602  |
| ACTH: pg/mL (mean ± SD)º                      | 73.3 ± 50.5  | 91.6 ± 67.3  | 0.282    |
| MRI (visible lesions): micro/macro (n)º       | 54/28       | 11/6        | 0.928    |
| MRI: maximum diameter, mm (mean ± SD)º        | 9.1 ± 4.1   | 9.0 ± 4.2   | 0.955    |
| PS Fs 800 h: µg/dL (mean ± SD)                 | 2.2 ± 2.4   | 2.7 ± 2.3   | 0.738    |
| PS ACTH: pg/mL (mean ± SD)                    | 10.1 ± 9.2  | 5.0 ± 2.2   | 0.347    |
| PS desmopressin: Fs, µg/dL (mean ± SD)        | 2.7 ± 4.0 (n = 35) | 3.1 ± 4.4 (n = 7) | 0.999  |
| PS glucocorticoid use: months (mean ± SD)     | 12.4 ± 7.6  | 9.3 ± 9.0   | 0.062    |
| Pathology: adenoma ACTH+/normal pituitary     | 73/10       | 13/4        | 0.250    |
| Follow-up: months (mean ± SD)                 | 124.3 (83.7)| 187.7 (112.6)| 0.013**  |
| Recurrence: %                                 | 35          | 50          | 0.531    |
| Time of recurrence: months (mean ± SD)        | 67.1 ± 53.7 | 60.6 ± 46.0 | 0.896    |

* p value by Student’s t-test
** p value by Mann–Whitney test; NA not appreciable, SD standard deviation

ºAt diagnosis of ACTH-dependent Cushing’s syndrome; NP no pregnancy, PP previous pregnancy to Cushing’s disease diagnosis, PA pregnancy after pituitary surgery, Fs serum cortisol (Reference [R]: 5–25 µg/dL), NSC nocturnal salivary cortisol (R: <120 ng/dL); UC urinary cortisol (R: 30–300 µg/24 h); ACTH, R: < 60 pg/mL, MRI magnetic resonance imaging, PS post-surgical

Table 2  Post-surgical and long-term outcome for all patients (n = 113)

| Parameter                                      | Remission       | Recurrence      | p        |
|-----------------------------------------------|-----------------|-----------------|----------|
| Number (%)                                    | 70 (62.0)       | 43 (38.0)       | NA       |
| Age: years (mean ± SD)º                       | 31.9 ± 7.7      | 29.0 ± 7.0      | 0.047b   |
| Fs 800 h: µg/dL (mean ± SD)º                  | 25.7 ± 22.8     | 23.5 ± 8.3      | 0.812    |
| NSC: ng/dL (mean ± SD)º                       | 1089.3 ± 2845.8 | 546.1 ± 675.7   | 0.251    |
| UC: µg/24 h (mean ± SD)º                      | 1121.9 ± 3968.8 | 775.6 ± 562.9   | 0.474    |
| ACTH: pg/mL (mean ± SD)º                      | 74.9 ± 59.9     | 79.8 ± 39.7     | 0.099    |
| MRI (visible lesions): micro/macro (n)º       | 43/18           | 22/16           | 0.199    |
| MRI: maximum diameter (mm) (mean ± SD)º       | 8.8 ± 4.3       | 9.5 ± 3.8       | 0.272    |
| MRI: sinus cavernous invasion (n)º            | 0               | 4               | 0.029c   |
| PS Fs: µg/dL (mean ± SD)                      | 2.0 ± 1.8       | 2.8 ± 3.2       | 0.173    |
| PS ACTH: pg/mL (mean ± SD)                    | 8.4 ± 8.1       | 14.2 ± 10.6     | 0.053    |
| PS desmopressin: Fs, µg/dL (mean ± SD)        | 1.7 ± 2.9       | 4.7 ± 5.2       | 0.070    |
| PS glucocorticoid use: months (mean ± SD)     | 12.3 ± 7.7      | 11.2 ± 8.2      | 0.565    |
| Pathology: adenoma ACTH+/normal pituitary (n) | 60/7            | 26/7            | 0.145    |
| Follow-up: months (mean ± SD)                 | 113.7 ± 86.3    | 173.9 ± 92.2    | 0.001*   |
| Pregnancy: number of patients (n)             | 39              | 28              | 0.969    |
| Pregnancy: previous PS/after PS (n)           | 28/11           | 17/11           | 0.341    |

*p value by Mann–Whitney test

ºAt diagnosis of ACTH-dependent Cushing’s syndrome; Fs serum cortisol (Reference [R]: 5–25 µg/dL), NSC nocturnal salivary cortisol (R: <120 ng/dL); UC urinary cortisol (R: 30–300 µg/24 h); ACTH, R: < 60 pg/mL, MRI magnetic resonance imaging, PS post-surgical

bStudent’s t-test

cFisher’s test; NA not appreciable, SD standard deviation
Discussion

To date, there is no single factor to predict the recurrence of CD in the long-term follow-up of patients. Previous studies showed that several factors, such as PS serum cortisol, PS ACTH, recovery of the HPA axis/return of the circadian rhythm of cortisol secretion, the extent of glucocorticoid replacement, early responses of ACTH and/or serum cortisol to secretagogues, among others [6, 7], can contribute to a recurrence. This fact can be explained by the rarity of the disease, the heterogeneity of studies, studies with a small number of patients and/or short time of follow-up and lack of consensus for recurrence criteria diagnosis. However, even patients with “rigid” criteria of remission and “low risk” can present a recurrence in the long-term follow-up with a non-negligible frequency.

This study is the first to evaluate the influence of pregnancy on the recurrence rate in a group of reproductive-age female CD patients that initially show post-surgical remission (n = 113). This group recurred at a rate of 38%, with a median of 48 months (range 8–240) after pituitary surgery, similar to a recurrence rate of overall patients, 30.9% (76/246). This relative higher recurrence rate in comparison to mean of literature may be explained by the great long-term surveillance, 30 years, in our study.

Even though the patients having pregnancy after pituitary surgery presented a higher recurrence rate of 50%, there was no significant difference in relation to other subgroups (NP/PP) according to the survival-free recurrence curve. This higher recurrence rate in the PA could be due to the subgroup being younger and having had longer follow-up time than the other.

Other parameters at diagnosis and PS periods for predicting recurrence were analyzed in this study. Recurrence patients showed a higher sinus cavernous invasion. Additionally, the lower survival-free recurrence was related to higher PS plasma ACTH more than 68.2 pg/mL at 5th PS Day and normal pituitary at pathological analyses.

We decided to study the influence of pregnancy on the recurrence rate of post-surgical CD patients because in our clinic experience, we occasionally observe early recurrence in patients some months after pregnancy, even in patients considered “low risk”. We suggest that hormonal changes that occur during the pregnancy may stimulate putative tumor cell remnants. There is no similar study in the literature. However, one interesting study analyzed the impact of pregnancy on progression of corticotropic tumor after bilateral adrenalectomy in 11 patients with 20 pregnancies, and it concluded that pregnancy does not accelerate corticotropic tumor growth and ACTH increase in Nelson’s syndrome [13].

One exploratory study published in 2018 presented a relatively high frequency of pregnancy-associated CD. This retrospective study included 64 women with confirmed CD but 64% in reproductive age. Pregnancy-associated CD was defined as clinical picture of Cushing’s onset within one year of childbirth. They found 27% of patients with pregnancy-associated CD and suggested a possible causal relationship related to the stress of pregnancy and pituitary corticotroph hyperactivity in the peripartum time. However, this study does not focus the recurrence of the patients [14].

Table 3 Post-surgical and long-term outcomes in relation to pregnancy history (n = 67)

| Parameter                                    | Remission | Recurrence | p    |
|----------------------------------------------|-----------|------------|------|
| Pregnancy: number of patients (n)            | 39        | 28         | 0.969|
| Pregnancy: number per patient (mean ± SD)    | 2.0 ± 0.7 | 2.0 ± 0.8  | 0.969|
| Weight gain during pregnancy: kg (mean ± SD) * | 13.3 ± 7.9| 13.1 ± 6.1 | 0.726|
| Delivery: normal/cesarean: %a                | 39.3/60.7 | 22.7/77.3  | 0.213|
| Delivery time: term/premature: %a            | 87.1/12.9 | 90.0/10.0  | 0.999|
| Newborn weight: g (mean ± SD)a               | 3196.7 ± 817.9 | 3224.5 ± 405.0 | 0.891|
| Newborn size: cm (mean ± SD)a                | 48.9 ± 2.7 | 49.5 ± 2.8 | 0.976|
| Maternal complications: n°                    | 8         | 5          | NA   |
| Fetal/Newborn complications: n°               | 4         | 7          | NA   |

*aData from pregnancy/newborn closer to CD diagnosis or recurrence; NA not appreciable, SD standard deviation
Two years after, another study very similar to that also presented 27.1% of pregnancy-associated CD in 70 patients using the same definition of pregnancy-associated CD that 2018’s study [15].

A healthy pregnancy is considered a transient physiologic state of ‘hypercortisolism’ [16]. There is a state of increased HPA axis function, leading to increased circulating cortisol and ACTH levels, reaching values in the range seen in Cushing’s syndrome (CS). These changes may lead to a misdiagnosis of CS during this period, with clinical features mimicking those seen in patients with CS. However, these changes lack the specific clinical manifestations of CS [9].

The mechanisms of ACTH increase during normal pregnancy are not fully elucidated, but they may include placental synthesis and the release of biologically active corticotropin-releasing hormone (CRH) and ACTH, pituitary desensitization to cortisol feedback, or enhanced pituitary responses to corticotropin-releasing factors, such as vasopressin and CRH [9, 10]. conditions that could stimulate the remnants of corticotropic tumor cells and cause CD recurrence.

On the other hand, the CRH-binding protein is elevated during the first two trimesters of pregnancy, but it decreases considerably in the final trimester, and bioavailable plasmatic CRH is consequently elevated [10, 17, 18].

CD in pregnancy is a rare phenomenon with few cases reported in the literature, and most of them are ACTH-independent [10]. CD is associated with fetal morbidity and mortality. When untreated, fetal mortality is nearly 20%, and treatment reduces but does not abolish this adverse outcome. Maternal morbidity includes hypertension, hyperglycemia, and eclampsia [19].

This study had some limitations that could influence the results. This study was retrospective and had a relatively small number of patients in each subgroup. Obstetric history was collected through telephone or email contacts in a portion of patients. However, we believe that the final number of included patients and quality of data were appropriate to perform this study.

We conclude that in our cohort, there was no difference in the recurrence rate in female patients according to pregnancy history. However, other studies with higher numbers of patients are necessary to confirm these data.

Author contributions All authors contributed to the study conception and design. Material preparation, data collection and analysis were performed by LML, MJBT and MCM. The first draft of the manuscript was written by LML and MCM and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

Compliance with ethical standards

Conflict of interest The authors declare no competing interests.

Ethical approval The Ethical and Research Committees of our institution approved the study. For this type of study, formal consent is not required. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

References

1. M. Fleseriu, R. Auchus, I. Bancos, A. Ben-Shlomo, J. Bertherat, N.R. Biermasz, C.L. Boguszewski, M.D. Bronstein, M. Buchfelder, J.D. Carmichael, F.F. Casanueva, F. Castinetti, P. Chanson, J. Findling, M. Gadelia, E.B. Geer, A. Giustina, A. Grossman, M. Gurnell, K. Ho, A.G. Iochiimescu, U.B. Kaiser, N. Karavitaki, L. Katzenelson, D.F. Kelly, A. Lacroix, A. McCormack, S. Melmed, M. Molitch, P. Mortini, J. Newell-Price, L. Nieman, A.M. Pereira, S. Petersenn, R. Pivonello, H. Raff, M. Reincke, R. Salvadori, C. Scaroni, I. Shimon, C.A. Stratakis, B. Swearingen, A. Tabarin, Y. Takahashi, M. Theodoropoulou, S. Tsagarakis, E. Valassi, E.V. Varlamov, G. Vila, J. Wass, S.M. Webb, M.C. Zatelli, B.M.K. Biller, Consensus on diagnosis and management of Cushing’s disease: a guideline update. Lancet Diabetes Endocrinol. 12, 847–875 (2021)

2. L.K. Nieman, B.M. Biller, J.W. Findling, M.H. Murad, J. Newell-Price, M.O. Savage, A. Tabarin, Endocrine Society. treatment of Cushing’s syndrome: An Endocrine Society Clinical Practice Guideline. J. Clin. Endocrinol. Metab. 100, 2807–2831 (2015)

3. R. Pivonello, M. De Leo, A. Cozzolino, A. Colao, The Treatment of Cushing’s Disease. Endocr. Rev. 36, 385–486 (2015)

4. M.C. Machado, A.E. Alcantara, A.C. Pereira, V.A. Cescao, N.R.C. Musolino, B.B. de Mendonça, M.D. Bronstein, M.C. Fragoso, Negative correlation between tumour size and cortisol/ACTH ratios in patients with Cushing’s disease harbouring microadenomas or macroadenomas. J. Endocrinol. Invest 39, 1401–1409 (2016)

5. C.G. Patil, D.M. Prevedello, S.P. Lad, M.L. Vance, M.O. Thorner, L. Katzenelson, E.R. Laws Jr. Late recurrences of Cushing’s disease after initial successful transsphenoidal surgery. J. Clin. Endocrinol. Metab. 93, 358–362 (2008)

6. D.J. Romanholi, M.C. Machado, C.C. Pereira, D.S. Danilovic, M.A. Pereira, V.A. Cescao, M.B. Cunha Neto, N.R.C. Musolino, B.B. de Mendonça, L.R. Salgado, Role for postoperative cortisol response to desmopressin in predicting the risk for recurrent Cushing’s disease. Clin. Endocrinol. (Oxf.). 69, 117–122 (2008)

7. K.I. Alexandraki, G.A. Kaltzas, A.M. Isidori, H.L. Storr, F. Afshar, I. Sabin, S.A. Akker, S.L. Chew, W.M. Drake, J.P. Monson, G.M. Besser, A.B. Grossman, Long-term remission and recurrence rates in Cushing’s disease: predictive factors in a single-centre study. Eur. J. Endocrinol. 166, 639–648 (2013)

8. B.R. Carr, C.R. Parker Jr, J.D. Madden, P.C. MacDonald, J.C. Porter, Maternal plasma adrenocorticotropic and cortisol relationships throughout human pregnancy. Am. J. Obstet. Gynecol. 139, 416–422 (1981)
9. J.R. Lindsay, L.K. Nieman. The hypothalamic-pituitary-adrenal axis in pregnancy: challenges in disease detection and treatment. Endocr. Rev. 26, 775–799 (2005)

10. M.D. Bronstein, M.C. Machado, M.C. Fragoso, Management of Endocrine Disease: Management of pregnant patients with Cushing’s syndrome. Eur. J. Endocrinol. 173, R85–R91 (2015)

11. G. Tirabassi, E. Falloia, R. Papa, G. Furlani, M. Boscaro, G. Arnaldi, Use of the desmopressin test in the differential diagnosis of pseudo-Cushing state from Cushing’s disease. J. Clin. Endocrinol. Metab. 95, 1115–1122 (2010)

12. M.C. Machado, M.C. Fragoso, A.C. Moreira, C.L. Boguszewski, L.N. Vieira, L.A. Naves, L. Vilar, L.A. Araújo, M.A. Czepielweski, M.R. Gadelha, N.R. Musolino, P.A. Miranda, M.D. Bronstein, A. Ribeiro-Oliveira Jr, Recommendations of the Neuroendocrinology Department of the Brazilian Society of Endocrinology and Metabolism for the diagnosis of Cushing’s disease in Brazil. Arch. Endocrinol. Metab. 60, 267–286 (2016)

13. F.R. Jornayvaz, G. Assie, M. Bienvenu-Perrard, J. Coste, L. Guignat, J. Bertherat, S. Silvera, X. Bertagna, P. Legmann, Pregnancy does not accelerate corticotroph tumor progression in Nelson’s syndrome. J. Clin. Endocrinol. Metab. 96, 658–662 (2011)

14. S.K. Palejwala, A.R. Conger, A.A. Eisenberg, P. Cohan, C.F. Griffiths, G. Barkhoudarian, D.F. Kelly, Pregnancy-associated Cushing’s disease? An exploratory retrospective study. Pituitary 6, 584–592 (2018)

15. K. Tang, L. Lu, M. Feng, H. Zhang, K. Chen, X. Sun, H. Zhu, R. Wang, Z. Lu, The incidence of pregnancy-associated Cushing’s disease and its relation to pregnancy: a retrospective study. Front. Endocrinol. (Lausanne). 11, 305 (2020)

16. R. Pivonello, M.C. De Martino, R.S. Auriemma, C. Alviggi, L.F. Grasso, A. Cozzolino, M. De Leo, G. De Placido, A. Colao, G. Lombardi, Pituitary tumors and pregnancy: the interplay between a pathologic condition and a physiologic status. J. Endocrinol. Invest 37, 99–112 (2014)

17. E. Demey-Ponsart, J.M. Foidart, J. Sulon, J.C. Sodoyez, Serum CBG, free and total cortisol and circadian patterns of adrenal function in normal pregnancy. J. Steroid Biochem. 16, 165–169 (1982)

18. B. Wetzka, B. Sehringer, W.R. Schäfer, S. Biller, C. Hör, E. Benedek, W.R. Deppert, H.P. Zahradnik, Expression patterns of CRH, CRH receptors, and CRH binding protein in human gestational tissue at term. Exp. Clin. Endocrinol. Diabetes 111, 154–161 (2003)

19. J.R. Lindsay, J. Jonklaas, E.H. Oldfield, L.K. Nieman, Cushing’s syndrome during pregnancy: personal experience and review of the literature. J. Clin. Endocrinol. Metab. 90, 3077–3083 (2005)